Jennerex

Jennerex enrolls first patient in phase IIb liver cancer trial

Friday, November 4, 2011 11:33 AM
Jennerex has initiated enrollment and the first patient has
been randomized in a phase IIb clinical trial called TRAVERSE.  The trial
is evaluating the use of JX-594 to treat patients with advanced liver
cancer, also known as hepatocellular carcinoma (HCC), who failed prior
therapy with sorafenib (NexavarR), the only approved drug for advanced
HCC.  In addition, Jennerex earned a milestone payment from its
development and commercialization partner, Transgene, based on the
randomization of the first patient in the TRAVERSE clinical trial.

More... »


Jennerex completes $8.6 million financing round

Monday, August 15, 2011 01:55 PM

Jennerex, a private clinical-stage biotherapeutics company, has completed a successful private placement financing round with gross proceeds of approximately $8.6 million.

More... »


Jennerex names James M. Burke vice president of clinical research

Tuesday, March 1, 2011 08:00 AM

Jennerex, a cancer biotherapeutics company, has appointed James M. Burke, M.D., vice president, clinical research. Dr. Burke will be responsible for global clinical research activities related to Jennerex pipeline compounds.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.